TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35986475

Group type: EXPERIMENTAL
Intervention: 30 cm PID with 1.02 mm thick Al alloy filter and rectangular collimator
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard intraoral radiography methods
Number of subjects: 125
Study: 34022912

Group type: EXPERIMENTAL
Intervention: House Improvement (HI)
Number of subjects: 20013

Group type: EXPERIMENTAL
Intervention: Larval Source Management (LSM)
Number of subjects: 20013

Group type: EXPERIMENTAL
Intervention: House Improvement + Larval Source Management (HI + LSM)
Number of subjects: 20013

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20013
Study: 32221160

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 34265255

Group type: EXPERIMENTAL
Intervention: Progressive exercise (≤6 sessions)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Best practice advice (one session)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection then progressive exercise
Number of subjects: 708

Group type: COMPARATOR
Intervention: Corticosteroid injection then best practice advice
Number of subjects: 708
Study: 32268257

Group type: EXPERIMENTAL
Intervention: Augmented biofeedback training alongside traditional physical therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Augmented biofeedback training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of augmented biofeedback training and traditional physical therapy
Number of subjects: 45
Study: 35334900

Group type: EXPERIMENTAL
Intervention: Cow milk formula (CMF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric extensive protein hydrolysate formula (EHF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EHF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clostridia at 3-4 months
Number of subjects: 30
Study: 34485754

Group type: EXPERIMENTAL
Intervention: Calcium chloride (15 mg/kg) administered intravenously as a bolus at the beginning of weaning from CPB
Number of subjects: 818

Group type: COMPARATOR
Intervention: 0.9% sodium chloride administered intravenously as a bolus at the beginning of weaning from CPB
Number of subjects: 818
Study: 33607392

Group type: EXPERIMENTAL
Intervention: Late-eveners (≥3 times/week)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Late-eveners
Number of subjects: 348

Group type: COMPARATOR
Intervention: Reference group (non-late-eaters)
Number of subjects: 348
Study: 34963654

Group type: EXPERIMENTAL
Intervention: Intervention group (reduced inappropriate media exposure)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Media exposure
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Stressful life events (SLE)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Harsh parenting
Number of subjects: 613
Study: 34788233

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) plus standard care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study: 32703177

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy with claw toes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Peripheral neuropathy without claw toes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-neuropathic with claw toes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-neuropathic without claw toes
Number of subjects: 40
Study: 36219509

Group type: EXPERIMENTAL
Intervention: MAGiC
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study: 34424563

Group type: EXPERIMENTAL
Intervention: Weed presence from emergence until the two true-leaf stage
Number of subjects: 4

Group type: COMPARATOR
Intervention: Weed removal at the two true-leaf stage
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Weed addition at the two true-leaf stage until harvest
Number of subjects: 4
Study: 32739611

Group type: EXPERIMENTAL
Intervention: Kabochan engagement group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 103
Study: 35101993

Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 30

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 30
Study: 34479732

Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the posterior ulnar recurrent artery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the inferior ulnar collateral artery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contrast agent applied to the superior ulnar collateral artery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiologic blood flow simulation
Number of subjects: 20
Study: 35863991

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) during second-line chemotherapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (CRS)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Non-Bevacizumab (non-BEV) during second-line chemotherapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 138
Study: 33472921

Group type: EXPERIMENTAL
Intervention: IV tPA treatment
Number of subjects: 255

Group type: COMPARATOR
Intervention: No acute intervention (control)
Number of subjects: 255
Study: 33377265

Group type: EXPERIMENTAL
Intervention: Vinegar drink containing 25 mmol acetate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study: 35970278

Group type: EXPERIMENTAL
Intervention: 1 gram of IV TXA preoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: No TXA (control group)
Number of subjects: 100
Study: 33741504

Group type: EXPERIMENTAL
Intervention: MPLA
Number of subjects: 30

Group type: COMPARATOR
Intervention: LPS
Number of subjects: 30
Study: 35556322

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ; 140 ml containing 800 mg nitrate per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (140 ml nitrate-depleted BRJ, daily)
Number of subjects: 14
Study: 32093630

Group type: COMPARATOR
Intervention: Treatment 1 (T1) - messages with information on their own adherence levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment 2 (T2) - messages with information on their own adherence and peer adherence levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36112539

Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) stove and fuel intervention
Number of subjects: 3195
Study: 34241574

Group type: EXPERIMENTAL
Intervention: Physician-assisted death (PAD) for psychiatric suffering
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Physician-assisted death (PAD) for somatic disease
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reasons for supporting psychiatric PAD
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reasons for not supporting psychiatric PAD
Number of subjects: 500
Study: 32902831

Group type: EXPERIMENTAL
Intervention: Guideline release (2019 Canadian Guideline for Physical Activity throughout Pregnancy)
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: General Population, Academics, Exercise Specialists, Medical Professionals tweeting about prenatal PA
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Geographical distribution of Tweets
Number of subjects: 1995
Study: 35709207

Group type: EXPERIMENTAL
Intervention: Multimedia pain management education (PME) through seven educational CDs at home
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF) pain management education in seven weekly sessions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 32139267

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 μg/day)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no eldecalcitol)
Number of subjects: 226
Study: 34228132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33396567

Group type: EXPERIMENTAL
Intervention: Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) at a dosage of 1.8 g/day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study: 35314131

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control Preferences Scale (CPS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: OPTION5
Number of subjects: 72
Study: 33117349

Group type: EXPERIMENTAL
Intervention: High throughput screening platform using one-bead-one-compound (OBOC) libraries for IgE epitope detection.
Number of subjects: 0
Study: 34378861

Group type: EXPERIMENTAL
Intervention: MYL‐1601D
Number of subjects: 71
Study: 33225949

Group type: EXPERIMENTAL
Intervention: Sexual recombination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asexual reproduction
Number of subjects: 0
Study: 616512450

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study: 35995130

Group type: EXPERIMENTAL
Intervention: School-supervised asthma therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enhanced usual care (receipt of an educational asthma workbook)
Number of subjects: 26
Study: 34171959

Group type: EXPERIMENTAL
Intervention: Vericiguat (target dose 10 mg once daily)
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 32375595

Group type: EXPERIMENTAL
Intervention: Mindfulness training focusing on present-moment attention and awareness
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mindfulness (non-judgmental acceptance facet)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 300
Study: 34999610

Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 units mixed with 100 mL of normal saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (100 mL of normal saline)
Number of subjects: 0
Study: 33634589

Group type: EXPERIMENTAL
Intervention: liraglutide (0.6, 1.2, and 1.8 mg/day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 134
Study: 32791720

Group type: EXPERIMENTAL
Intervention: Ear molding treatment for 2 weeks within 3 days after birth
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (waiting list)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ear molding at 6th week if spontaneous recovery does not occur
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Physician and parent assessment of improvement, parent's anxiety, depression, and quality of life
Number of subjects: 190
Study: 36512912

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg (Arm 1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks (Arm 2)
Number of subjects: 82
Study: 33323579

Group type: EXPERIMENTAL
Intervention: Therapeutic contact lens (TCL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no TCL)
Number of subjects: 40
Study: 32962591

Group type: EXPERIMENTAL
Intervention: Mini-midvastus (MMV) approach
Number of subjects: 54

Group type: COMPARATOR
Intervention: Medial parapatellar (MPP) approach
Number of subjects: 54
Study: 35397540

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 34404690

Group type: EXPERIMENTAL
Intervention: Pressure controlled continuous mandatory ventilation (PC-CMV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Volume controlled continuous mandatory ventilation (VC-CMV)
Number of subjects: 27
Study: 32619648

Group type: EXPERIMENTAL
Intervention: Omission of week 5 chemotherapy
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Dose reductions/delays of week 5 chemotherapy
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Receiving the target radiotherapy dose in >42 days
Number of subjects: 940
Study: 33296320

Group type: EXPERIMENTAL
Intervention: Stochastic dominant learning swarm optimizer
Number of subjects: 0
Study: 32858196

Group type: EXPERIMENTAL
Intervention: SI-locking screws (superoinferior)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AP-locking screws (anteroposterior)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Divergent screw orientation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Parallel screw orientation
Number of subjects: 20
Study: 35040196

Group type: EXPERIMENTAL
Intervention: Intensive treatment (INT)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Conventional treatment (CONV)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control population without diabetes
Number of subjects: 568
Study: 33078318

Group type: COMPARATOR
Intervention: Flap fixation using sutures (FFS)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Flap fixation using tissue glue (FFG)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Conventional wound closure (CON)
Number of subjects: 339
Study: 32986075

Group type: EXPERIMENTAL
Intervention: Computerized virtual advisor program (virtual)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Previously validated peer advisor program (human)
Number of subjects: 245
Study: 35650311

Group type: EXPERIMENTAL
Intervention: ENDOSWIR near-infrared optical imaging device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to SWIR light)
Number of subjects: 0
Study: 34847302

Group type: EXPERIMENTAL
Intervention: RelyX Ultimate cement under normal atmospheric pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem cement under normal atmospheric pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Ultimate cement under hyperbaric pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem cement under hyperbaric pressure
Number of subjects: 40
Study: 34076569

Group type: EXPERIMENTAL
Intervention: Tai Chi group (TCG)
Number of subjects: 65
Study: 32072743

Group type: EXPERIMENTAL
Intervention: HIV combination prevention package including universal testing and treatment
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: HIV testing with streamlined, algorithmic approach
Number of subjects: 48000
Study: 35086944

Group type: EXPERIMENTAL
Intervention: High amount/moderate intensity exercise (16 kcal/kg/week at 50% V̇O2 reserve)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: High/vigorous exercise (16 kcal/kg/week at 75% V̇O2 reserve)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low/moderate exercise (10 kcal/kg/week at 50% V̇O2 reserve)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low/moderate plus diet (10 kcal/kg/week at 50% V̇O2 reserve plus calorically restricted diet)
Number of subjects: 162
Study: 35368954

Group type: EXPERIMENTAL
Intervention: Nimodipine combined with magnesium sulfate
Number of subjects: 96

Group type: COMPARATOR
Intervention: Magnesium sulfate (single drug group)
Number of subjects: 96
Study: 32436287

Group type: EXPERIMENTAL
Intervention: TCA 35%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phenol 88%
Number of subjects: 20
Study: 35758171

Group type: EXPERIMENTAL
Intervention: Social determinants of health domains (economic stability, health care, education, neighborhood and built environment, social and community context)
Number of subjects: 2505

Group type: EXPERIMENTAL
Intervention: Access to Healthcare
Number of subjects: 2505
Study: 33004239

Group type: EXPERIMENTAL
Intervention: DAR-901 vaccine (1 mg, three intradermal injections at 0, 2, and 4 months)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Saline placebo (three intradermal injections at 0, 2, and 4 months)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: DAR-901 vaccine (1 mg)
Number of subjects: 667
Study: 32893741

Group type: EXPERIMENTAL
Intervention: WATER
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CARBON
Number of subjects: 12

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 12
Study: 34980634

Group type: EXPERIMENTAL
Intervention: Regional Repolarisation Instability Index (R2I2)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Peak Electrical Restitution Slope
Number of subjects: 440
Study: 33257778

Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling in the first 3 months post HSCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: General qualitative education without reinforcement (Control Group)
Number of subjects: 46
Study: 35750727

Group type: EXPERIMENTAL
Intervention: Digital surgical guide (CAD/CAM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional implant guide (traditional impression)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 33759846

Group type: EXPERIMENTAL
Intervention: Online interactive case-based training on shared decision-making (SDM)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Online interactive case-based training on evidence-based practice (EBP) related to medication use in autism
Number of subjects: 97
Study: 32756101

Group type: EXPERIMENTAL
Intervention: Movimente intervention program (teacher training, improvements in PA environment, educational strategies)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Control group (traditional schedule)
Number of subjects: 999
Study: 35060851

Group type: EXPERIMENTAL
Intervention: Prednisolone (15 mg/m2 for 6 days)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 271
Study: 34837824

Group type: EXPERIMENTAL
Intervention: ctDCS (cathodal transcranial direct current stimulation) at -1.0 mA for 20 minutes over 5 days
Number of subjects: 25
Study: 32127304

Group type: EXPERIMENTAL
Intervention: CAD/CAM splints
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional splints
Number of subjects: 30
Study: 35285944

Group type: EXPERIMENTAL
Intervention: Oral low-dose isotretinoin (0.2–0.4 mg/kg/d) combined with 30% salicylic acid chemical peeling
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral low-dose isotretinoin
Number of subjects: 33

Group type: COMPARATOR
Intervention: 30% salicylic acid chemical peeling
Number of subjects: 33
Study: 32692788

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical budesonide irrigations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral doxycycline
Number of subjects: 50
Study: 35008039

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Athlete-driven KR
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: KR
Number of subjects: 29

Group type: COMPARATOR
Intervention: No Feedback (NoFb)
Number of subjects: 29
Study: 32467145

Group type: EXPERIMENTAL
Intervention: Ph‐like cases
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ph‐like profile
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ph‐like patients
Number of subjects: 88
Study: 32687588

Group type: EXPERIMENTAL
Intervention: Reduced-dose capecitabine plus cetuximab as maintenance therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fluorouracil-based chemotherapy combined with cetuximab (induction therapy)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Induction therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 47
Study: 36348150

Group type: EXPERIMENTAL
Intervention: LED therapy (LEDT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 42
Study: 34579095

Group type: EXPERIMENTAL
Intervention: RES-500 (500 mg RES/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RES-1000 (1000 mg RES/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RES (both doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35048107

Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Control (no polypill)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan) in participants with pNASH
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Control (no polypill) in participants without pNASH
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Participants with pNASH
Number of subjects: 2400
Study: 32895043

Group type: EXPERIMENTAL
Intervention: Dietary education (4 sessions)
Number of subjects: 112
Study: 36469332

Group type: EXPERIMENTAL
Intervention: Nonmydriatic ultra-widefield (NM UWF) imaging on the day of a scheduled diabetes clinic visit
Number of subjects: 740

Group type: COMPARATOR
Intervention: Usual screening (encouraged to arrange optometrist screening)
Number of subjects: 740
Study: 32613229

Group type: EXPERIMENTAL
Intervention: iCanCope app (smartphone-based pain self-management program)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Symptom tracking only app (control)
Number of subjects: 60
Study: 32340074

Group type: COMPARATOR
Intervention: Conventional with Prevention (C + P)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Biological with Prevention (B + P)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Prevention Alone (PA)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: All treatment arms (C + P, B + P, PA)
Number of subjects: 1144
Study: 35623727

Group type: EXPERIMENTAL
Intervention: V block
Number of subjects: 140

Group type: COMPARATOR
Intervention: H block
Number of subjects: 140
Study: 33945339

Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) autograft with lateral extra-articular tenodesis (LET)
Number of subjects: 0
Study: 33355421

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher intake of folates, vitamin D, vitamin E, magnesium, zinc, and copper
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Recommended sleep duration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Increase of BMI percentile
Number of subjects: 75
Study: 34936615

Group type: EXPERIMENTAL
Intervention: Robot-assisted lymphaticovenous anastomosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual lymphaticovenous anastomosis
Number of subjects: 20